{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:56:23Z","timestamp":1787064983274,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The therapeutic effectiveness of immune checkpoint inhibitors (ICIs) in bladder cancer varies among individuals. Identifying reliable predictors of response to these therapies is crucial for optimizing patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed 348 bladder cancer patients treated with ICIs, with additional validation using data from 248 patients at our institution who underwent PD-L1 immunohistochemical staining. We examined patient smoking history, clinicopathological characteristics, and immune phenotypes. The main focus was the correlation between smoking history and immunotherapy outcomes. Multivariate logistic and Cox proportional hazard regressions were used to adjust for confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study cohort comprised 348 bladder cancer patients receiving ICIs. Among them, 116 (33.3%) were never smokers, 197 (56.6%) were former smokers (median pack-years = 28), and 35 (10.1%) were current smokers (median pack-years = 40). Analysis revealed no statistically significant difference in overall survival across different smoking statuses (objective response rates were 11.4% for current smokers, 17.2% for never smokers, and 22.3% for former smokers;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.142, 0.410, and 0.281, respectively). However, a notable trend indicated a potentially better response to immunotherapy in former smokers compared to current and never smokers. In the validation cohort of 248 patients from our institution, immunohistochemical analysis showed that PD-L1 expression was significantly higher in former smokers (55%) compared to current smokers (37%) and never smokers (47%). This observation underscores the potential influence of smoking history on the tumor microenvironment and its responsiveness to ICIs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, our study demonstrates the importance of incorporating smoking history in predicting the response to immunotherapy in bladder cancer patients, highlighting its role in personalized cancer treatment approaches. Further research is suggested to explore the comprehensive impact of lifestyle factors on treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1404812","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:20:47Z","timestamp":1718238047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessing the predictive value of smoking history for immunotherapy outcomes in bladder cancer patients"],"prefix":"10.3389","volume":"15","author":[{"given":"Jianqiu","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuogui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjiong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1038\/551S33a","article-title":"Bladder cancer","volume":"551","author":"Grayson","year":"2017","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'Olio","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"104321","DOI":"10.1016\/j.critrevonc.2024.104321","article-title":"Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis","volume":"196","author":"Monteiro","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2318815","DOI":"10.1080\/21645515.2024.2318815","article-title":"Immune regulation and the tumor microenvironment in anti-PD-1\/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis","volume":"20","author":"Huang","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.01.019","article-title":"Impact of performance status on oncologic outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitor: A systematic review and meta-analysis","volume":"9","author":"Kawada","year":"2023","journal-title":"Eur Urol Focus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03498-0","article-title":"PD-L1 testing in urothelial bladder cancer: essentials of clinical practice","volume":"39","author":"Rouanne","year":"2021","journal-title":"World J Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-020-0174-y","article-title":"TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials","volume":"27","author":"Choucair","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1090838","article-title":"Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2018.07.007","article-title":"Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma","volume":"230","author":"Nagahashi","year":"2018","journal-title":"J Surg Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3991","article-title":"Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02482-9","article-title":"Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies","volume":"23","author":"Sotelo","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12943-023-01912-w","article-title":"CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182\u20135p\/CYP1B1 axis","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002309","article-title":"Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis","volume":"14","author":"Snyder","year":"2017","journal-title":"PLoS Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-006-0111-z","article-title":"Cigarette smoking: cancer risks, carcinogens, and mechanisms","volume":"391","author":"Hecht","year":"2006","journal-title":"Langenbecks Arch Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.12.003","article-title":"Effects of tobacco smoke on immunity, inflammation and autoimmunity","volume":"34","author":"Arnson","year":"2010","journal-title":"J Autoimmun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mas.21392","article-title":"Pathophysiology of tobacco smoke exposure: recent insights from comparative and redox proteomics","volume":"33","author":"Colombo","year":"2014","journal-title":"Mass Spectrom Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"108365","DOI":"10.1016\/j.mrrev.2021.108365","article-title":"Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer","volume":"787","author":"Caliri","year":"2021","journal-title":"Mutat Res Rev Mutat Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21630","article-title":"An update on the immune landscape in lung and head and neck cancers","volume":"70","author":"Carlisle","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","article-title":"Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications","volume":"14","author":"Fang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discovery"},{"key":"B26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/01621459.2022.2105703","article-title":"A generalized integration approach to association analysis with multi-category outcome: an application to a tumor sequencing study of colorectal cancer and smoking","volume":"118","author":"Zheng","year":"2023","journal-title":"J Am Stat Assoc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003178","article-title":"Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants","volume":"17","author":"Larsson","year":"2020","journal-title":"PLoS Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/tobaccocontrol-2021-056575","article-title":"Smoking cessation: health system challenges and opportunities","volume":"31","author":"Pipe","year":"2022","journal-title":"Tob Control"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntaa156","article-title":"Cigarette smoking reduction and health risks: A systematic review and meta-analysis","volume":"23","author":"Chang","year":"2021","journal-title":"Nicotine Tob Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1404812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:20:51Z","timestamp":1718238051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1404812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2024.1404812"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1404812","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"article-number":"1404812"}}